Pacira BioSciences (FRA:82P) Float Percentage Of Total Shares Outstanding: 69.17% (As of Jul. 08, 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
75 GF Score
Price €22.40
GF Value €25.72
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Float Percentage Of Total Shares Outstanding?

Pacira BioSciences FRA:82P +2.75% 75 Float Percentage Of Total Shares Outstanding is 69.17% as of Jul. 08, 2026. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pacira BioSciences's float shares is 27.22 Mil. Pacira BioSciences's total shares outstanding is 39.35 Mil. Pacira BioSciences's float percentage of total shares outstanding is 69.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pacira BioSciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pacira BioSciences's Institutional Ownership is 63.98%.

FRA:82P
75GF Score
Pacira BioSciences Inc FRA:82P
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Pacira BioSciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=27.22/39.35
=69.17%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 69.17% mean?
Pacira BioSciences (FRA:82P) has a Float Percentage Of Total Shares Outstanding of 69.17% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Float Percentage Of Total Shares Outstanding too high?
Pacira BioSciences' current Float Percentage Of Total Shares Outstanding is 69.17%. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Float Percentage Of Total Shares Outstanding compare to ETON and AMPH?
Pacira BioSciences' Float Percentage Of Total Shares Outstanding of 69.17% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Float Percentage Of Total Shares Outstanding is 69.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Float Percentage Of Total Shares Outstanding of 69.17%. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 69.17%. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Float Percentage Of Total Shares Outstanding is 69.17% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.

Key valuation signals for FRA:82P:

  • Float Percentage Of Total Shares Outstanding: 69.17%
  • GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for FRA:82P

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.40
Price
€25.72
GF Value